✦ LIBER ✦

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

✍ Scribed by Devineni, Damayanthi; Vaccaro, Nicole; Polidori, David; Rusch, Sarah; Wajs, Ewa

Book ID: 121810274
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 437 KB
Volume: 36
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2014.02.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and Pharmacodynamics of

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

✍ Devineni, Damayanthi; Curtin, Christopher R.; Polidori, David; Gutierrez, Maria 📂 Article 📅 2013 🏛 Sage Publications 🌐 English ⚖ 605 KB

Clinical Pharmacokinetics and Pharmacody

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

✍ Kasichayanula, Sreeneeranj; Liu, Xiaoni; LaCreta, Frank; Griffen, Steven C.; Bou 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 522 KB

Canagliflozin, a novel inhibitor of sodi

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

✍ S. Sha; D. Devineni; A. Ghosh; D. Polidori; S. Chien; D. Wexler; K. Shalayda; K. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

Efficacy and Safety of Canagliflozin, a

Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Versus Glimepiride in Patients with Type 2 Diabetes on Background Metformin

✍ Leiter, Lawrence A.; Cefalu, William T.; Niskanen, Leo; Xie, John; Millington, D 📂 Article 📅 2012 🏛 Canadian Diabetes Association 🌐 English ⚖ 62 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

✍ S. Kasichayanula; M. Chang; M. Hasegawa; X. Liu; N. Yamahira; F. P. LaCreta; Y. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

The Effect of Moderate Hepatic Impairmen

The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor

✍ Zhang, Wenhui; Krauwinkel, Walter J. J.; Keirns, James; Townsend, Robert W.; Las 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 328 KB